Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension

J Am Coll Cardiol. 2012 Jul 3;60(1):80-1. doi: 10.1016/j.jacc.2012.03.025. Epub 2012 May 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects*
  • Aspartate Aminotransferases / blood
  • Chemical and Drug Induced Liver Injury / enzymology
  • Chemical and Drug Induced Liver Injury / epidemiology
  • Chemical and Drug Induced Liver Injury / etiology*
  • Drug Administration Schedule
  • Endothelin A Receptor Antagonists*
  • Endothelins / antagonists & inhibitors
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Incidence
  • Liver / drug effects*
  • Liver / enzymology
  • Liver / pathology
  • Liver / physiopathology
  • Liver Function Tests
  • Male
  • Middle Aged
  • Phenylpropionates / administration & dosage*
  • Phenylpropionates / adverse effects*
  • Pyridazines / administration & dosage*
  • Pyridazines / adverse effects*
  • Risk Factors
  • United States / epidemiology

Substances

  • Antihypertensive Agents
  • Endothelin A Receptor Antagonists
  • Endothelins
  • Phenylpropionates
  • Pyridazines
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • ambrisentan